NICE rejects GSK's Revolade
This article was originally published in Scrip
Executive Summary
NICE, the National Institute for Health and Clinical Excellence, still has too many doubts about the long-term effectiveness of GlaxoSmithKline's oral thrombopoietin receptor agonist Revolade eltrombopag, called Promacta in the US, to recommend its use on the NHS for patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP).